{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:57:17Z","timestamp":1793141837942,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.annonc.2026.05.695","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:16:35Z","timestamp":1779203795000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-year survival with tebentafusp in metastatic uveal melanoma"],"prefix":"10.1016","author":[{"given":"S.","family":"Piperno-Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-7057","authenticated-orcid":false,"given":"M.O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"R.J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-9796","authenticated-orcid":false,"given":"J.J.","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.S.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"A.M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-4312","authenticated-orcid":false,"given":"S.","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gastaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Demidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Milhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"Bernicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-4600","authenticated-orcid":false,"given":"J.-F.","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-3250","authenticated-orcid":false,"given":"P.D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2026.05.695_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.annonc.2026.05.695_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.695_bib3","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.695_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"13","key":"10.1016\/j.annonc.2026.05.695_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.695_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.annonc.2026.05.695_bib7","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.695_bib8","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.05.695_bib9","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1200\/JCO.2024.42.16_suppl.9529","article-title":"Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)","volume":"42","author":"Ikeguchi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.695_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.695_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005854","article-title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review","volume":"11","author":"Al-Showbaki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.05.695_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115634","article-title":"Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres","volume":"227","author":"van der Kooij","year":"2025","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.05.695_bib13","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.1016\/j.annonc.2024.08.1197","article-title":"1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)","volume":"35","author":"Nathan","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.05.695_bib14","article-title":"Real-world experience of tebentafusp for uveal melanoma via an Australian access program","volume":"41","author":"Inderjeeth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.05.695_bib15","article-title":"Tebentafusp in metastatic uveal melanoma patients: results of the Italian expanded access program","volume":"43","author":"Rossi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.695_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2284","article-title":"1656P Clinical and molecular outcomes of tebentafusp in metastatic uveal melanoma (MUM): a retrospective cohort of 168 patients","volume":"36","author":"Sanchez","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.695_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2265","article-title":"1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting","volume":"34","author":"Ribeiro","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.695_bib18","article-title":"164P Real-world study on tebentafusp use in metastatic uveal melanoma in France: interim analysis of the PRIMUM.0 study","volume":"28","author":"Rodrigues","year":"2025","journal-title":"Immuno-Oncol Technol"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.695_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.695_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.695_bib21","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41467-025-57470-w","article-title":"Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer","volume":"16","author":"G\u00fc\u00e7","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.695_bib22","article-title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","volume":"6","author":"Sacco","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.annonc.2026.05.695_bib23","first-page":"A650","article-title":"619 Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma","volume":"10","author":"Watson","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.695_bib24","doi-asserted-by":"crossref","first-page":"101994","DOI":"10.1016\/j.xcrm.2025.101994","article-title":"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies","volume":"6","author":"Lopez","year":"2025","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.695_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf323","article-title":"Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients","volume":"30","author":"Lim","year":"2025","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.695_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-019-0513-4","article-title":"Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?","volume":"7","author":"Wang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.695_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.annonc.2026.05.695_bib28","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1245\/s10434-022-12368-5","article-title":"Tumor growth rate as a predictive marker for recurrence and survival after liver resection in patients with liver metastases of uveal melanoma","volume":"29","author":"Ramtohul","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.695_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/CMR.0000000000000952","article-title":"Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma","volume":"34","author":"Roshardt Prieto","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annonc.2026.05.695_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115386","article-title":"Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp","volume":"220","author":"Beylergil","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.695_bib31","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:18:07Z","timestamp":1782850687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426008793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0923753426008793"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.695","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year survival with tebentafusp in metastatic uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Immunocore Holdings Plc. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}